β-Thalassemia intermedia: a comprehensive overview and novel approaches

被引:62
作者
Asadov, Chingiz [1 ]
Alimirzoeva, Zohra [1 ]
Mammadova, Tahira [1 ]
Aliyeva, Gunay [1 ]
Gafarova, Shahla [1 ]
Mammadov, Jeyhun [2 ]
机构
[1] Inst Hematol & Transfusiol, M Gashgai Str 87, AZ-1007 Baku, Azerbaijan
[2] Thalassemia Ctr, Fataly Khan Khoysky Str 128, AZ-1072 Baku, Azerbaijan
关键词
ss-Thalassemia intermedia; Non-transfusion-dependent thalassemia; Transfusion; Complications; Novel treatment; RECOMBINANT-HUMAN-ERYTHROPOIETIN; TRANSFUSION-DEPENDENT THALASSEMIA; PULMONARY ARTERIAL-HYPERTENSION; BONE-MINERAL DENSITY; SICKLE-CELL-DISEASE; QUALITY-OF-LIFE; RED-BLOOD-CELLS; IRON OVERLOAD; INEFFECTIVE ERYTHROPOIESIS; HYDROXYUREA THERAPY;
D O I
10.1007/s12185-018-2411-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
beta-Thalassemia intermedia is a clinical condition of intermediate gravity between beta-thalassemia minor, the asymptomatic carrier, and beta-thalassemia major, the transfusion-dependent severe anemia. It is characterized by a significant clinical polymorphism, which is attributable to its genetic heterogeneity. Ineffective erythropoiesis, chronic anemia, and iron overload contribute to the clinical complications of thalassemia intermedia through stepwise pathophysiological mechanisms. These complications, including splenomegaly, extramedullary erythropoiesis, iron accumulation, leg ulcers, thrombophilia, and bone abnormalities can be managed via fetal hemoglobin induction, occasional transfusions, chelation, and in some cases, stem cell transplantation. Given its clinical diversity, thalassemia intermedia patients require tailored approaches to therapy. Here we present an overview and novel approaches to the genetic basis, pathophysiological mechanisms, clinical complications, and optimal management of thalassemia intermedia.
引用
收藏
页码:5 / 21
页数:17
相关论文
共 161 条
  • [1] Cardiac involvement in thalassemia intermedia: a multicenter study
    Aessopos, A
    Farmakis, D
    Karagiorga, M
    Voskaridou, E
    Loutradi, A
    Hatziliami, A
    Joussef, J
    Rombos, J
    Loukopoulos, D
    [J]. BLOOD, 2001, 97 (11) : 3411 - 3416
  • [2] Thalassemia intermedia today: should patients regularly receive transfusions?
    Aessopos, Athanassios
    Kati, Maria
    Meletis, John
    [J]. TRANSFUSION, 2007, 47 (05) : 792 - 800
  • [3] Treatment of 100 chronic thalassemic leg wounds by plasma-rich platelets
    Afradi, Hojjat
    Saghaei, Yassaman
    Kachoei, Zohre A.
    Babaei, Vahid
    Teimourian, Shahram
    [J]. INTERNATIONAL JOURNAL OF DERMATOLOGY, 2017, 56 (02) : 171 - 175
  • [4] Alimirzoeva Z, 2014, LEUK RES S1, V38, P526
  • [5] ALMOMEN AKM, 1991, ACTA HAEMATOL-BASEL, V86, P46
  • [6] Comparative study of pulmonary circulation and myocardial function in patients with β-thalassemia intermedia with and without hydroxyurea, a case-control study
    Amoozgar, Hamid
    Farhani, Nahal
    Khodadadi, Neda
    Karimi, Mehran
    Cheriki, Sirous
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2011, 87 (01) : 61 - 67
  • [7] Intestinal HIF2α promotes tissue-iron accumulation in disorders of iron overload with anemia
    Anderson, Erik R.
    Taylor, Matthew
    Xue, Xiang
    Ramakrishnan, Sadeesh K.
    Martin, Angelical
    Xie, Liwei
    Bredell, Bryce X.
    Gardenghi, Sara
    Rivella, Stefano
    Shah, Yatrik M.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (50) : E4922 - E4930
  • [8] Efficacy of Hydroxyurea in Providing Transfusion Independence in β-Thalassemia
    Ansari, Saqib H.
    Shamsi, Tahir S.
    Ashraf, Mushtaq
    Perveen, Kousar
    Farzana, Tasneem
    Bohray, Muneera
    Erum, Sajida
    Mehboob, Tabassum
    [J]. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2011, 33 (05) : 339 - 343
  • [9] Asadov C, 2016, GEORGIAN MED NEWS, V255, P86
  • [10] Asadov C, 2012, KLIN LAB DIAGN, V1, P16